Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.84
AMRN's Cash-to-Debt is ranked lower than
82% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. AMRN: 0.84 )
Ranked among companies with meaningful Cash-to-Debt only.
AMRN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.98 Max: No Debt
Current: 0.84
Equity-to-Asset -0.05
AMRN's Equity-to-Asset is ranked lower than
91% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. AMRN: -0.05 )
Ranked among companies with meaningful Equity-to-Asset only.
AMRN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.82  Med: -0.05 Max: 0.83
Current: -0.05
-0.82
0.83
Piotroski F-Score: 5
Altman Z-Score: -6.99
Beneish M-Score: -2.66
WACC vs ROIC
13.03%
-765.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -50.45
AMRN's Operating Margin % is ranked higher than
57% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. AMRN: -50.45 )
Ranked among companies with meaningful Operating Margin % only.
AMRN' s Operating Margin % Range Over the Past 10 Years
Min: -691.08  Med: -148.59 Max: -50.45
Current: -50.45
-691.08
-50.45
Net Margin % -66.38
AMRN's Net Margin % is ranked higher than
53% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. AMRN: -66.38 )
Ranked among companies with meaningful Net Margin % only.
AMRN' s Net Margin % Range Over the Past 10 Years
Min: -630.82  Med: -122.45 Max: -66.38
Current: -66.38
-630.82
-66.38
ROA % -51.74
AMRN's ROA % is ranked lower than
65% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. AMRN: -51.74 )
Ranked among companies with meaningful ROA % only.
AMRN' s ROA % Range Over the Past 10 Years
Min: -549.69  Med: -66.17 Max: -26.61
Current: -51.74
-549.69
-26.61
ROC (Joel Greenblatt) % -4343.67
AMRN's ROC (Joel Greenblatt) % is ranked lower than
78% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. AMRN: -4343.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMRN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -231547.22  Med: -8240.48 Max: -1589.48
Current: -4343.67
-231547.22
-1589.48
3-Year Revenue Growth Rate 57.20
AMRN's 3-Year Revenue Growth Rate is ranked higher than
88% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. AMRN: 57.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMRN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 57.2
Current: 57.2
0
57.2
3-Year EBITDA Growth Rate -30.60
AMRN's 3-Year EBITDA Growth Rate is ranked lower than
82% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. AMRN: -30.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMRN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.6 Max: 66.3
Current: -30.6
0
66.3
3-Year EPS without NRI Growth Rate -31.60
AMRN's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. AMRN: -31.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMRN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -81.1  Med: -16.5 Max: 88.5
Current: -31.6
-81.1
88.5
GuruFocus has detected 1 Warning Sign with Amarin Corp PLC $AMRN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMRN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

AMRN Guru Trades in Q4 2015

Jim Simons 264,900 sh (New)
» More
Q1 2016

AMRN Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q3 2016

AMRN Guru Trades in Q3 2016

Jim Simons 50,600 sh (New)
Paul Tudor Jones 29,802 sh (New)
» More
Q4 2016

AMRN Guru Trades in Q4 2016

Jim Simons 386,000 sh (+662.85%)
Paul Tudor Jones 10,998 sh (-63.10%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ESPR, NAS:JNCE, NAS:ASND, OTCPK:BIESF, NAS:ACRS, NAS:PGNX, NAS:CLLS, NAS:ZIOP, OTCPK:SXMDF, NAS:RPTP, NAS:INSY, NAS:AMAG, NAS:INSM, NAS:AKAO, NAS:VSAR, NAS:EPZM, OTCPK:BPMUF, OTCPK:PFSCF, NAS:MESO, NAS:IMMU » details
Traded in other countries:EH3A.Germany,
Amarin Corp PLC is a biopharmaceutical company with expertise in lipid science. The Company is engaged in commercialization and development of therapeutics to improve cardiovascular health.

Amarin Corp PLC, formerly known as Ethical Holdings plc was incorporated under the laws of England and Wales on March 1, 1989 under the Companies Act 1985. It is a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. The Company's product Vascepa (icosapent ethyl) capsules is approved by the U.S. Food and Drug Administration for the use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG>500mg/dL) hypertriglyceridemia. On January 28, 2013 the Company commenced full commercial launch of Vascepa. The Company refers to its second indication for Vascepa as the ANCHOR indication. The FDA views the proposed ANCHOR indication as ostensibly and impliedly an indication to reduce cardiovascular risk. In addition, in December 2011, the Company announced commencement of patient dosing in cardiovascular outcomes study of Vascepa, titled REDUCE-IT or Reduction of Cardiovascular Events with EPA-Intervention Trial. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing cardiovascular events in a high risk patient population on statin therapy. On January 28, 2013, the Company commenced full commercial launch of Vascepa in the United States for use in the MARINE indication. The Company now markets Vascepa in the United States through sales force of approximately 150 sales professionals and also employed marketing and medical affairs personnel to support commercialization of Vascepa. As of February 1, 2014, over 16,000 clinicians had written prescriptions for Vascepa. In November 2010, the Company reported top-line data for the MARINE trial. Vascepa was well tolerated in the MARINE trial, with a safety profile comparable to placebo and there were no treatment-related serious adverse events observed. The Company uses third party manufacturers and suppliers to manufacture clinical and commercial quantities of ethyl-EPA, which constitutes the only active pharmaceutical ingredient within Vascepa, to encapsulate, bottle and package Vascepa and to maintain inventory of Vascepa. The Company currently relies on Patheon for the encapsulation of Vascepa. The Companies competitors include GlaxoSmithKline plc and AbbVie, Inc., and Niaspan. The Company is subject to regulation by government authorities, including FDA.

Ratios

vs
industry
vs
history
PS Ratio 4.96
AMRN's PS Ratio is ranked higher than
73% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. AMRN: 4.96 )
Ranked among companies with meaningful PS Ratio only.
AMRN' s PS Ratio Range Over the Past 10 Years
Min: 2.8  Med: 46.1 Max: 600
Current: 4.96
2.8
600
Current Ratio 1.92
AMRN's Current Ratio is ranked lower than
76% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. AMRN: 1.92 )
Ranked among companies with meaningful Current Ratio only.
AMRN' s Current Ratio Range Over the Past 10 Years
Min: 0.27  Med: 2.99 Max: 14.08
Current: 1.92
0.27
14.08
Quick Ratio 1.65
AMRN's Quick Ratio is ranked lower than
74% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. AMRN: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
AMRN' s Quick Ratio Range Over the Past 10 Years
Min: 0.22  Med: 2.99 Max: 14.08
Current: 1.65
0.22
14.08
Days Inventory 214.38
AMRN's Days Inventory is ranked lower than
74% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. AMRN: 214.38 )
Ranked among companies with meaningful Days Inventory only.
AMRN' s Days Inventory Range Over the Past 10 Years
Min: 209.74  Med: 262.76 Max: 650.68
Current: 214.38
209.74
650.68
Days Sales Outstanding 56.08
AMRN's Days Sales Outstanding is ranked higher than
52% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. AMRN: 56.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.49  Med: 54.45 Max: 61.73
Current: 56.08
50.49
61.73
Days Payable 64.39
AMRN's Days Payable is ranked higher than
53% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. AMRN: 64.39 )
Ranked among companies with meaningful Days Payable only.
AMRN' s Days Payable Range Over the Past 10 Years
Min: 64.39  Med: 146.87 Max: 195.34
Current: 64.39
64.39
195.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.00
AMRN's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. AMRN: -16.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMRN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -271.2  Med: -54.7 Max: 21.2
Current: -16
-271.2
21.2

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.11
AMRN's Price-to-Median-PS-Value is ranked higher than
97% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. AMRN: 0.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMRN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.07 Max: 7.97
Current: 0.11
0.01
7.97
Earnings Yield (Greenblatt) % -6.22
AMRN's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. AMRN: -6.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMRN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6.36  Med: 501.9 Max: 7646.9
Current: -6.22
-6.36
7646.9

More Statistics

Revenue (TTM) (Mil) $130.1
EPS (TTM) $ -0.41
Beta1.68
Short Percentage of Float2.26%
52-Week Range $1.41 - 3.65
Shares Outstanding (Mil)272.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 166 385 531
EPS ($) -0.17 0.24 0.57
EPS without NRI ($) -0.17 0.24 0.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AMRN

Headlines

Articles On GuruFocus.com
Morning Coffee: Widely Held International Guru Stocks Near 52-Week Lows May 23 2014 
Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN Jan 07 2013 
Steven Cohen Adds Amarin Corp. Awaiting Drug Approval, Buys Hyatt Hotels Mar 28 2012 
Soros Funds’ Great Britain Buys and Sells Apr 13 2011 

More From Other Websites
AMARIN CORP PLC\UK Files SEC form 8-K, Shareholder Director Nominations Mar 27 2017
Amarin Corporation CEO, John Thero, to Chair the American Heart Association’s Heart & Stroke Ball... Mar 21 2017
Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major... Mar 16 2017
Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in... Mar 15 2017
AMARIN CORP PLC\UK Financials Mar 08 2017
Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
AMARIN CORP PLC\UK Files SEC form 10-K, Annual Report Mar 01 2017
Q4 2016 Amarin Corporation PLC Earnings Release - Before Market Open Feb 28 2017
AMARIN CORP PLC\UK Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 28 2017
Amarin reports 4Q loss Feb 28 2017
Amarin reports 4Q loss Feb 28 2017
Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on... Feb 28 2017
Amarin to Report Fourth Quarter and Full Year 2016 Results and Host Conference Call on February... Feb 22 2017
Amarin to Participate in the Leerink Partners 6th Annual Global Healthcare Conference Feb 09 2017
AMARIN CORP PLC\UK Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Jan 25 2017
AMARIN CORP PLC\UK Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... Jan 20 2017
Amarin Announces Debt Restructuring and Related Private Placement of Exchangeable Senior Notes Jan 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)